Proven Health VCT Plc : Result of Meeting
12 Mars 2012 - 6:28PM
UK Regulatory
TIDMNHF
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE
UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY JURISDICTION IN
WHICH THE SAME COULD BE UNLAWFUL. THE INFORMATION CONTAINED HEREIN DOES NOT
CONSTITUTE AN OFFER OF SECURITIES FOR SALE IN ANY JURISDICTION, INCLUDING IN THE
UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA.
PROVEN HEALTH VCT PLC
12 MARCH 2012
Results of General Meeting
The Board of ProVen Health VCT plc (the "Company") refers to the Circular
published by the Company on 10 February 2012 in relation to the participation of
the Company in the recommended proposals for the reconstruction and winding up
of Longbow Growth and Income VCT plc, an Enhanced Share Buyback, an Offer for
Subscription, the proposed change of its investment policy and the cancellation
of its share premium account.
Following LGIV Shareholders voting in favour of the resolutions proposed at the
LGIV First General Meeting of the holder of LGIV Shares on 7 March 2012, the
Board of the Company is pleased to announce that all of the resolutions proposed
at the General Meeting of the Company this morning in connection with the
Proposals were both duly passed.
All five Resolutions were passed on a show of hands. Resolutions 1 and 4 were
passed as ordinary resolutions and resolutions 2, 3 and 5 were passed as special
resolutions. The results of the proxy votes on the Resolutions were as follows:
Resolution 1 (to grant the directors authority to allot New Ordinary Shares in
connection with the LGIV Scheme)
Votes for*: 2,077,567 Ordinary Shares
Votes against: 51,213 Ordinary Shares
Votes withheld**: 4,776 Ordinary Shares
Resolution 2 (authority to allot New Ordinary Shares pursuant to the Enhanced
Share Buyback and the Offer for Subscription and disapplication of pre-emption
rights)
Votes for*: 2,034,930 Ordinary Shares
Votes against: 82,206 Ordinary Shares
Votes withheld**: 16,420 Ordinary Shares
Resolution 3 (authority to make market purchases in connection with the Enhanced
Share Buyback)
Votes for*: 2,059,859 Ordinary Shares
Votes against: 73,697 Ordinary Shares
Votes withheld**: Nil Ordinary Shares
Resolution 4 (change to investment policy)
Votes for*: 2,105,344 Ordinary Shares
Votes against: 28,212 Ordinary Shares
Votes withheld**: Nil Ordinary Shares
Resolution 5 (cancellation of the share premium account)
Votes for*: 2,065,345 Ordinary Shares
Votes against: 38,918 Ordinary Shares
Votes withheld**: 29,293 Ordinary Shares
* the "Votes for" include those votes giving the Chairman discretion.
** A "Vote withheld" is not a vote in law and is not counted in the
calculation of the votes for or against the resolution.
A copy of the Resolutions has been submitted to the National Storage Mechanism
and will shortly be available for inspection at http://www.hemscott.com/nsm.do.
Expected timetable
It should be noted that the Proposals remain conditional upon inter alia the
approval of LGIV Shareholders at the LGIV Second General Meeting to be held at
10.00 a.m. on 16 March 2012.
The expected timetable in relation to the implementation of the Proposals is as
follows:
2012
Calculation Date close of business on 13 March
LGIV Second General Meeting 10.00 a.m. on 16 March
Effective Date of the LGIV Scheme 16 March
Admission and dealings commence in the New 8.00 a.m. on 19 March
Ordinary Shares issued pursuant to the LGIV Scheme
CREST accounts credited with New Ordinary Shares 8.00 a.m. on 19 March
issued pursuant to the LGIV Scheme
Share and tax certificates despatched in respect Week commencing 9 April
of New Ordinary Shares issued pursuant to the LGIV
Scheme
Notes:
1. The dates set out in the expected timetable above may be adjusted by
the Company, in which event details of the new dates will be notified to the UK
Listing Authority and the London Stock Exchange and an announcement will be made
through a regulatory information service that is on the list of regulatory
information services maintained by the Financial Services Authority.
2 All references to time in this announcement are to London time.
Definitions
Terms defined in the circular published by the Company on 10 February 2012 have
the same meanings in this announcement unless the context requires otherwise.
Further information
For further information please contact:
Steven Tuckley Beringea LLP 020 7845 7820
Douglas Armstrong Dickson Minto W.S. 020 7649 6823
Notes
This announcement does not constitute or form part of any offer to issue or
sell, or any solicitation of any offer to subscribe or purchase, any investment
in any jurisdiction, nor shall it (or the fact of its distribution) form the
basis of, or be relied on in connection with, any contract therefor.
The issue and the distribution of this announcement and the Circular in certain
jurisdictions may be restricted by law and persons into whose possession any
document or other information referred to this announcement, the Circular comes
should inform themselves about and observe any such restriction. Any failure to
comply with these restrictions may constitute a violation of the securities laws
of any such jurisdiction.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Proven Health VCT Plc via Thomson Reuters ONE
[HUG#1593378]
Proven Health (LSE:PHV)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Proven Health (LSE:PHV)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Proven Health (London Stock Exchange): 0 recent articles
Plus d'articles sur Proven Health